THE ABILITY to create custom-made drugs that target specific cell receptors or specific cytokines is heralding a new era in the treatment of inflammatory diseases. This is particularly relevant for psoriasis because the agents that have been developed block specific steps in the pathogenesis of this disease. In this issue of the ARCHIVES, Singri and coauthors1 present an excellent mechanism-oriented description of the new biologic therapies emerging for treatment of psoriasis.
Lebwohl M. New Developments in the Treatment of Psoriasis. Arch Dermatol. 2002;138(5):686-688. doi:10.1001/archderm.138.5.686